Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Viridian Therapeutics, Inc.\DE (VRDN) Total Liabilities: 2014-2024

Historic Total Liabilities for Viridian Therapeutics, Inc.\DE (VRDN) over the last 11 years, with Dec 2024 value amounting to $70.8 million.

  • Viridian Therapeutics, Inc.\DE's Total Liabilities rose 15.16% to $74.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $74.2 million, marking a year-over-year increase of 15.16%. This contributed to the annual value of $70.8 million for FY2024, which is 46.20% up from last year.
  • Per Viridian Therapeutics, Inc.\DE's latest filing, its Total Liabilities stood at $70.8 million for FY2024, which was up 46.20% from $48.4 million recorded in FY2023.
  • Over the past 5 years, Viridian Therapeutics, Inc.\DE's Total Liabilities peaked at $70.8 million during FY2024, and registered a low of $11.2 million during FY2020.
  • For the 3-year period, Viridian Therapeutics, Inc.\DE's Total Liabilities averaged around $53.1 million, with its median value being $48.4 million (2023).
  • As far as peak fluctuations go, Viridian Therapeutics, Inc.\DE's Total Liabilities declined by 22.68% in 2020, and later surged by 150.28% in 2022.
  • Yearly analysis of 5 years shows Viridian Therapeutics, Inc.\DE's Total Liabilities stood at $11.2 million in 2020, then skyrocketed by 42.57% to $16.0 million in 2021, then surged by 150.28% to $40.0 million in 2022, then rose by 20.92% to $48.4 million in 2023, then surged by 46.20% to $70.8 million in 2024.